CureVac NV
NASDAQ:CVAC

Watchlist Manager
CureVac NV Logo
CureVac NV
NASDAQ:CVAC
Watchlist
Price: 2.99 USD 1.01% Market Closed
Market Cap: 670.7m USD
Have any thoughts about
CureVac NV?
Write Note

CureVac NV
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CureVac NV
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
CureVac NV
NASDAQ:CVAC
Cost of Revenue
-€116.3m
CAGR 3-Years
-102%
CAGR 5-Years
-46%
CAGR 10-Years
N/A
BioNTech SE
NASDAQ:BNTX
Cost of Revenue
-€599.8m
CAGR 3-Years
-117%
CAGR 5-Years
-112%
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Cost of Revenue
-€32.8m
CAGR 3-Years
-44%
CAGR 5-Years
-37%
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotest AG
XETRA:BIO
Cost of Revenue
-€467m
CAGR 3-Years
-6%
CAGR 5-Years
-10%
CAGR 10-Years
-4%
Formycon AG
XETRA:FYB
Cost of Revenue
-€54.8m
CAGR 3-Years
-27%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
No Stocks Found

CureVac NV
Glance View

Market Cap
670.8m USD
Industry
Biotechnology

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.

CVAC Intrinsic Value
4.32 USD
Undervaluation 31%
Intrinsic Value
Price

See Also

What is CureVac NV's Cost of Revenue?
Cost of Revenue
-116.3m EUR

Based on the financial report for Dec 31, 2023, CureVac NV's Cost of Revenue amounts to -116.3m EUR.

What is CureVac NV's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-46%

Over the last year, the Cost of Revenue growth was 27%. The average annual Cost of Revenue growth rates for CureVac NV have been -102% over the past three years , -46% over the past five years .

Back to Top